September 15, 2011

Oxigene’s Shares Jump On Favorable Cancer Treatment Data


Biopharmaceutical company Oxigene Inc. (OXGN) presented data that showed the company's zybrestat treatment helped increase the one-year survival rate of patients with larger anaplastic thyroid cancer tumors…The company said the data was derived from a comparison between the results of Oxigene's aggregate data from five independent Phase 1 and Phase 2 trials using zybrestat to treat patients with anaplastic thyroid cancer. Key findings include the fact that 13 patients, or 9.7% of all patients treated at the Mayo Clinic, survived one year or longer.

Wall Street Journal, 9/15/11

Tags: Research

Please sign in or register to post a reply.
Contact Us · Privacy Policy